Passage Bio Rg

Passage Bio, Inc., a Philadelphia‑based gene‑therapy company focusing on CNS disorders, has a pipeline of AAV‑delivered therapies for rare monogenic diseases including infantile GM1, Krabbe, FTD, ALS, and Huntington’s. It partners with Penn’s Gene Therapy Program and Catalent.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 60
HQ: Philadelphia

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
PASG	Passage Bio Rg Cap: 0.1B	EQUITY	NMS	USD	US7027121000	Active	📈